(Q34089089)

30 July 2017

1 reference

title

Public health paradoxes and the epidemiological impact of an HPV vaccine (English)

1 reference

30 July 2017

0 references

1 reference

1 reference

Garnett GP

1

1 reference

30 July 2017

Waddell HC

series ordinal

2

1 reference

30 July 2017

publication date

1 October 2000

1 reference

Journal of Clinical Virology

30 July 2017

published in

1 reference

30 July 2017

volume

19

1 reference

30 July 2017

issue

1-2

1 reference

30 July 2017

page(s)

101-111

1 reference

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900129-3

7 January 2021

Predicting the effect of varicella vaccine on subsequent cases of zoster and varicella

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900129-3

7 January 2021

Natural history of dysplasia of the uterine cervix

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900129-3

7 January 2021

Can papilloma virus testing be used to improve cervical cancer screening?

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900129-3

7 January 2021

Human papillomavirus testing as triage for atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesions: sensitivity, specificity, and cost-effectiveness.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900129-3

7 January 2021

Papillomavirus-like particles for serology and vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900129-3

7 January 2021

Do our current cervical cancer control strategies still make sense?

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900129-3

7 January 2021

Assessing HIV vaccine effects

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900129-3

7 January 2021

Vaccination against colonizing bacteria with multiple serotypes

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900129-3

7 January 2021

Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900129-3

7 January 2021

No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900129-3

7 January 2021

Human papillomavirus infection and other risk factors for cervical neoplasia: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900129-3

7 January 2021

The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900129-3

7 January 2021

Estimates of the worldwide incidence of 25 major cancers in 1990.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900129-3

7 January 2021

Papillomavirus-like particle vaccines for cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900129-3

7 January 2021

Evaluating cervical cancer screening programmes for developing countries

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900129-3

7 January 2021

Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900129-3

7 January 2021

Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-)effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900129-3

7 January 2021

Introduction of vaccines into the Third World

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900129-3

7 January 2021

Stage-specific treatment costs for cervical cancer in the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2800%2900129-3

7 January 2021

10.1016/S1386-6532(00)00129-3

Identifiers

DOI

1 reference

30 July 2017

1 reference